Ledby Chairman You Hongtao, Pharcin Pharma launched its IPO of A shares onShenzhen Stock Exchange on Oct. 20, 2017, realizing its debut in capital market, which raised
about 140 million yuan for building up its Phase V Production Base. The Company got the meaningful numbers 002907 as its stockcode.
InMay, 2016, Pharscin Pharma officially started to construct
the Phase V Production Base in Rongchang District,
Chongqing, China. This new production base is strictly
complying with ICH-GMP, and is going to pass cGMP
certification for achieving the company's goal of
In Aug. 2015, Pharscin Pharma founded another wholly
owned subsidiary, Chongqing Pharscin Pharmacy Retail
Chain Co., Ltd., expanding its business to pharmacy retail.
Pharscin Pharma finished its share reform at Aug. 2015 ,
indicating its start of its IPO project.
The building of Pharscin Biotech was officially in use for the
company headquarters and R&D center of Pharscin Pharma
in March, 2014. At the same year,Pharscin Pharma passed
the verification as Academician Expert Workstation.
In Dec. 2014, Pharscin Pharma scessfully acquired 16 drug
for dosage forms of freeze-driedpowder injection which further enriched the freeze-dried powder injection product series.
In Apr. 2012, Pharscin Pharma was awarded "China Famous Brand" title by the State Administration for Industry and
In Oct. 2011, Pharscin Pharma was granted "National Key
Hi-Tech Enterprise" and became the first company in
Chongqing passing the new GMP certification.
In Nov. 2010, PharscinPharma finish constructing its phase III production base adding API synthesis production line, GSP
warehouse and logistics system.
Pharscin Pharma extends its business to medical distribution by founding Chongqing Pharscin Medicine Co.,Ltd. in
Rongchang, Chongqing at Apr. 2009.
In Nov., 2006, the Chongqing Pharscin Biotech Co., Ltd. is
established at ChongqingLiangjiang New District and the
Phrascin Pharma Research Institute isestablished at the same year.
Inthe year of 2004, Phascin Pharma finished building its
phase II production base and expanded its dosage forms of
production facilities to powder injection, smalldose injection，
freeze-dried powder， soft capsule，powder， Chinese
traditional medicine extraction，among which the soft capsule production linebecame the first case in Chongqing.
The first self-built production base called as "phase I
production base" of Pharscin Pharma with its four production
lines（including tablets,capsules, granules, and API
synthesis）passed the GMP certification of NMPA ( former
CFDA) at Feb., 2002.
Pharscin Pharma got its first generic drug approval-Weidimei
( Hydrotalcid Tablet) which has become the best-selling
domestic Hydrotalcid Tablet after years of marketing
promoting. Now the gross sales revenue of Weidimei
(HydrotalcidTablet) is more than 100 million yuan annually and still keeps a stable growth rate up to date.
Chongqing Pharscin Pharmaceutical Co., Ltd.
（abbreviation：Pharscin Pharma）is established at
Rongchang District, Chongqing, China, on Nov.18th, 1996.